EvolutionaryScale, a pioneering startup, has successfully raised $142 million in a seed funding round led by notable figures such as ex-GitHub CEO Nat Friedman and Daniel Gross, with additional investment from Amazon and Nvidia’s NVentures. The company, founded by former Meta AI researchers, aims to leverage AI to generate novel proteins for scientific applications like drug discovery and materials science. Their latest AI model, ESM3, trained on a dataset of 2.78 billion proteins, can predict protein sequences and structures, potentially revolutionizing the process of protein engineering. EvolutionaryScale has already demonstrated the model’s capabilities by creating a new variant of green fluorescent protein. While the company plans to monetize through partnerships and usage fees, it might take a decade to see profitable therapeutic designs. With backing from tech giants and an ambitious vision, EvolutionaryScale is poised to push the boundaries of AI in biotechnology.
EvolutionaryScale Secures $142M to Revolutionize Protein Engineering with AI
EvolutionaryScale secures $142M to innovate protein engineering using AI.
1–2 minutes
TOP STORIES
Quantum computing is transforming industries, but it poses significant cybersecurity risks …
A coalition of state attorneys general has opened an investigation into OpenAI …
The U.S. government’s export control directive has forced Anthropic to disable its new AI models, raising questions about regulation and …
SpaceX’s recent deal with Google highlights its shift from aerospace to AI infrastructure …
Google is suing to dismantle the infrastructure behind an alleged massive AI-powered cybercrime operation …
AI usage continues to grow rapidly, even as public sentiment remains skeptical …
